Search for content, post, videos
Advertisement

BioInvent terminates Phase II study

mikael oredsson bioinvent

BioInvent International announces that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma.

The decision follows BioInvent’s review and discussion with the US Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016.

The terminated trial, which was performed in collaboration with Penn Medicine, targeted a specific population of multiple myeloma patients undergoing autologous stem cell transplantation with high-dose melphalan.

Advertisement

 

Advertisement